CLINICAL TRIALS PROFILE FOR YERVOY

All Clinical Trials for YERVOY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00170157 ↗	Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer	Completed	Medarex	Phase 2	2004-06-01	RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗	Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2004-06-01	RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗	Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer	Completed	U.S. Army Medical Research Acquisition Activity	Phase 2	2004-06-01	RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗	Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer	Completed	United States Department of Defense	Phase 2	2004-06-01	RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗	Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer	Completed	Mayo Clinic	Phase 2	2004-06-01	RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.

Clinical Trial Conditions for YERVOY

Condition Name

Condition Name for YERVOY
Intervention	Trials
Melanoma	42
Metastatic Melanoma	26
Renal Cell Carcinoma	14
Non-small Cell Lung Cancer	10

Condition MeSH

Condition MeSH for YERVOY
Intervention	Trials
Melanoma	88
Carcinoma	54
Carcinoma, Renal Cell	33
Lung Neoplasms	31

Clinical Trial Locations for YERVOY

Trials by Country

Trials by Country for YERVOY
Location	Trials
Japan	189
China	125
Australia	123
Canada	92
Spain	76

Trials by US State

Trials by US State for YERVOY
Location	Trials
Texas	106
California	93
Pennsylvania	75
Massachusetts	75
New York	71

Clinical Trial Progress for YERVOY

Clinical Trial Phase

Clinical Trial Phase for YERVOY
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	20
Phase 2/Phase 3	7

Clinical Trial Status

Clinical Trial Status for YERVOY
Clinical Trial Phase	Trials
Recruiting	107
Active, not recruiting	69
Completed	44

Clinical Trial Sponsors for YERVOY

Sponsor Name

Sponsor Name for YERVOY
Sponsor	Trials
Bristol-Myers Squibb	133
National Cancer Institute (NCI)	53
M.D. Anderson Cancer Center	35

Sponsor Type

Sponsor Type for YERVOY
Sponsor	Trials
Other	265
Industry	237
NIH	55

YERVOY: A Comprehensive Update on Clinical Trials, Market Analysis, and Projections

Last updated: January 4, 2025

Introduction to YERVOY

YERVOY, also known as ipilimumab, is a monoclonal antibody that targets the CTLA-4 receptor, playing a crucial role in cancer immunotherapy. Developed by Bristol Myers Squibb, YERVOY has been a game-changer in the treatment of various cancers, particularly melanoma and other advanced malignancies.

Clinical Trials and Efficacy

Long-Term Survival Benefits in Melanoma

Recent data from the CheckMate 067 trial has highlighted the long-term efficacy of YERVOY in combination with Opdivo (nivolumab) for patients with advanced melanoma. After a 10-year follow-up, the study revealed that 43% of patients who received the combination therapy were alive, significantly improving the median overall survival to 71.9 months. This is the longest reported median overall survival in a Phase III advanced melanoma trial to date[1].

Improved Survival in Hepatocellular Carcinoma

The CheckMate -9DW trial demonstrated that the combination of Opdivo and YERVOY significantly improved survival benefits compared to lenvatinib or sorafenib in patients with advanced hepatocellular carcinoma (HCC). The objective response rate for the combination was more than double that of the control arm, with a median duration of response of 30 months[4].

Market Analysis

Current Market Size and Growth

The YERVOY market was valued at USD 7.5 billion in 2023 and is projected to reach USD 15 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 8% from 2024 to 2031. This growth is driven by the expanding clinical uses and new indications for YERVOY, particularly in treating melanoma and non-small cell lung cancer[3].

Regional Analysis

The market for YERVOY is segmented geographically into North America, Europe, Asia-Pacific, South America, and the Middle-East and Africa. The increasing global prevalence of cancer and the need for sophisticated treatment solutions are key drivers of market growth across these regions. Strategic alliances and partnerships among pharmaceutical companies also support the market position of YERVOY[3].

Market Projections

Expanding Clinical Uses

The market for YERVOY is expected to grow significantly due to its proven effectiveness in cancer immunotherapy. The drug's use is expanding beyond melanoma to include other cancers such as non-small cell lung cancer. Ongoing clinical trials and the approval of new indications are further propelling the market growth[3].

Impact of Immunotherapy

Immunotherapies, including YERVOY, are becoming increasingly integral to cancer treatment algorithms. In the non-small cell lung cancer (NSCLC) market, for example, immunotherapies are projected to account for 65% of total sales by 2025, with YERVOY and other checkpoint inhibitors like Opdivo and Keytruda leading the charge[5].

Key Factors Driving Market Growth

Rising Global Prevalence of Cancer

The soaring incidence of cancer worldwide is a major driver of the YERVOY market. As cancer cases increase, the demand for effective and innovative treatments like YERVOY rises, contributing to market growth[3].

Continued R&D Initiatives

Pharmaceutical companies are investing heavily in research and development, which is driving the advancement of YERVOY and other immunotherapies. These initiatives are extending the clinical uses of YERVOY and enhancing its market position[3].

Strategic Alliances and Partnerships

Collaborations between pharmaceutical companies are crucial for the development and commercialization of YERVOY. These alliances support the market expansion by facilitating access to new technologies, markets, and patient populations[3].

Challenges and Opportunities

Safety Profile and Adverse Events

While the combination of Opdivo and YERVOY has shown significant efficacy, it also comes with a notable safety profile. Treatment-related adverse events (TRAEs) are common, with 84% of patients experiencing TRAEs of any grade. However, these adverse events are generally manageable with established protocols[4].

Market Competition

The immunotherapy market is highly competitive, with other checkpoint inhibitors like Keytruda and Tecentriq also vying for market share. However, YERVOY's established position and ongoing clinical successes help it maintain a strong market presence[5].

Conclusion

YERVOY has revolutionized the treatment landscape for advanced melanoma and other cancers, offering durable long-term survival benefits. With a growing market valued at USD 7.5 billion in 2023 and projected to reach USD 15 billion by 2031, YERVOY continues to be a cornerstone in cancer immunotherapy.

Key Takeaways

• Long-Term Efficacy: YERVOY in combination with Opdivo has demonstrated a 43% survival rate at 10 years for patients with advanced melanoma.
• Expanding Indications: YERVOY is being explored for use in various cancers, including hepatocellular carcinoma.
• Market Growth: The YERVOY market is expected to grow at a CAGR of 8% from 2024 to 2031.
• Global Prevalence: The rising incidence of cancer globally is driving the demand for YERVOY.
• R&D Initiatives: Continued research and development are extending the clinical uses of YERVOY.

FAQs

Q: What is YERVOY used for?

YERVOY (ipilimumab) is used primarily for the treatment of unresectable or metastatic melanoma. It is also being explored for use in other cancers such as hepatocellular carcinoma.

Q: How effective is the combination of Opdivo and YERVOY in melanoma treatment?

The combination of Opdivo and YERVOY has shown a significant improvement in overall survival for patients with advanced melanoma, with a 43% survival rate at 10 years.

Q: What are the key drivers of the YERVOY market growth?

The key drivers include the expanding clinical uses, rising global prevalence of cancer, continued R&D initiatives, and strategic alliances among pharmaceutical companies.

Q: What are the common adverse events associated with YERVOY?

Treatment-related adverse events (TRAEs) are common, with 84% of patients experiencing TRAEs of any grade. However, these adverse events are generally manageable.

Q: How does YERVOY compare to other immunotherapies in the market?

YERVOY competes with other checkpoint inhibitors like Keytruda and Tecentriq but maintains a strong market presence due to its established efficacy and ongoing clinical successes.

Sources

1. Biospace: BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years.
2. Biospace: Melanoma Market to Reach USD 8.9 Billion by 2034.
3. Market Research Intellect: Yervoy Market Size, Share, Industry Report 2024-31.
4. Bristol Myers Squibb: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival.
5. GlobalData: NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025.